GPR171 是一种 G 蛋白偶联受体 (GPCR),与 P2Y 受体具有近同源性。GPR171 在中脑导水管周围灰质内表达。BigLEN 是一种 16 氨基酸神经肽,源自神经内分泌分泌途径蛋白 proSAAS,已被确定为 GPR171 的内源性配体。据报道,GPR171 可调节 μ 阿片受体信号传导、镇痛、进食和焦虑行为。另一方面,GPR171 是癌症数据库分析中广为接受的 T 细胞特征基因,尽管其潜在的免疫功能尚未测试。根据早期发表的数据库,GPR171 表达往往在肿瘤浸润淋巴细胞 (TIL) 中上调,在黑色素瘤患者中,其表达在免疫疗法反应中显著增加。所有这些都意味着 GPR171 在 T 细胞免疫中可能发挥作用。
GPR171 is a G protein-coupled receptor (GPCR) with close homology to the P2Y receptors. GPR171 is expressed within the periaqueductal gray. BigLEN, a 16-amino acid neuropeptide derived from a neuroendocrine secretory pathway protein proSAAS, has been identified as the endogenous ligand for GPR171. GPR171 is reported to regulate mu opioid receptor signaling, antinociception, feeding and anxiety behaviors. On the other hand, GPR171 is a well-accepted T-cell signature gene in cancer database analysis, though its potential immune function is untested. Based on early published databases, GPR171 expression tends to be upregulated in tumor-infiltrating lymphocytes (TILs) and its expression in melanoma patients is significantly increased in response to immunotherapies. All these imply a possible role of GPR171 in T-cell immunity.
BigLEN(mouse) TFA 是一种 proSAAS 衍生的神经肽和 GPR171 激动剂,可调节小鼠的食物摄入,并通过依赖突触后 G 蛋白激活的过程抑制谷氨酸向室旁核小细胞神经元的释放。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号